Alessandro Aiuti is M.D., specialized in Immunology, and Ph.D. in Molecular and Cell Biology. In 1998 he obtained the National Board in Hematology.
Heis Deputy Director, Clinical Research Coordinator, and Head of Unit on Pathogenesis and Therapy of PIDof the San Raffaele Telethon Institute for Gene Therapy in Milan; Director of the Pediatric Immunohematology Unit, San Raffaele Hospital, Milan; full Professor of Pediatrics and Director of the Residency Program of Pediatrics, Vita-Salute San Raffaele University in Milan, Italy.
He is author of more than 180 peer reviewed publications (total citations of 10812, h-index Scopus 48). Full list of publications is available at here.
He is board member of the ESGCT since 2012, member of the Inborn Errors Working Party (IEWP) Studies Committee of the European Society for Bone and Marrow Transplantation (EBMT) (since 2015), member of ASGCT Hematologic and Immunologic Gene and Cell Therapy Committee (since 2016), Co-Chair of the Stem Cell and Gene Therapy WP of European Reference Network (ERN) on Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases Network (RITA) (since 2017), member of IRDiRC Orphan Drug Development Guidebook (ODDG) Task Force (since September 2018), and member (representing clinicians) of the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA) (as from July 1, 2019)
His main interests are hematology, immunology and pediatrics, particularly in the study of PID. His main domains of research are: HSC gene therapy for genetic diseases (PI of 5 clinical trials: ADA-SCID, WAS, beta thalassemia, MLD and MPS1), clonal dynamics of hematopoiesis, genetics and pathogenesis of primary immunodeficiencies. He has pioneered the EU market approval of the first ex vivo gene therapy for a genetic disease.